generation run 2026-05-08
62 min completedmodel pipeline-v5plan not recordedrun/df24a794…Selection
Verification
- record
- seen / partial
- working
The model's own caveats
- structural_inference
- safety_data_unverified
- safety_data_unverified
Reproduce
- inputs
- 30 source keys (listed under Sources)
- plan
- not recorded — template version, prompt hash and git SHA are written from 2026-09 onward
- model
- pipeline-v5
- streams
- none — agent transcripts are persisted from 2026-09 onward
22 searches — query, source, results, what was kept and why
| # | source | query | seen | kept | rationale |
|---|---|---|---|---|---|
| 1 | OpenAlex | clonazolam designer benzodiazepine | 10 | 5 | High citation count reviews covering clonazolam specifically |
| 2 | PubMed | PMID 32172178 | 1 | 1 | — |
| 3 | PubMed | PMID 36621072 | 1 | 1 | — |
| 4 | PubMed | clonazolam metabolism metabolites toxicology | 6 | 2 | — |
| 5 | PubMed | PMID 30367253 | 1 | 1 | — |
| 6 | PubMed | PMID 36281064 | 1 | 1 | — |
| 7 | PubMed | clonazolam pharmacology benzodiazepine | 15 | 10 | All directly relevant to clonazolam pharmacology or clinical effects |
| 8 | PubMed | clonazolam death overdose forensic | 3 | 2 | — |
| 9 | PubChem | clonazolam | 1 | 1 | Primary chemical identity verification |
| 10 | ClinicalTrials.gov · absence | clonazolam | 0 | 0 | — |
| 11 | WebSearch | clonazolam legal status scheduling US UK EU Canada Australia DEA | 10 | 2 | — |
| 12 | OpenAlex | clonazolam GABA benzodiazepine receptor potency characterization | 10 | 3 | — |
| 13 | PubMed | PMID 36988452 | 1 | 1 | — |
| 14 | WebSearch | WHO ECDD clonazolam critical review 43rd expert committee drug dependence 2022 pharmacology potency | 10 | 1 | — |
| 15 | WebSearch | clonazolam Leo Sternbach Upjohn synthesis 1971 patent history first synthesis | 10 | 1 | — |
| 16 | PubMed | clonazolam driving under influence DUID impaired | 2 | 1 | — |
| 17 | WebSearch | clonazolam half-life pharmacokinetics bioavailability hours duration | 10 | 2 | — |
| 18 | PubChem | CID 12317881 | 1 | 1 | — |
| 19 | PubMed | benzodiazepine opioid combination respiratory depression death risk | 3 | 1 | — |
| 20 | Crossref | DOI 10.1016/j.forsciint.2020.110237 | 1 | 1 | — |
| 21 | OpenAlex | Moosmann 2015 characterization four designer benzodiazepines clonazolam deschloroetizolam flubromazolam meclonazepam | 5 | 0 | — |
| 22 | WebSearch | clonazolam SMILES InChI structure 353 molecular formula | 10 | 2 | — |
62 claims by section — every cited sentence, checked against its source
safety22 · 16 ok
Claim in safety — inconclusiveinconclusiveworking →
Toxicology revealed 8-aminoclonazolam at 140 ng/mL in postmortem blood; cause of death was classified as cerebral and respiratory depression from acute clonazolam intoxication.supported
140 ng/mL 8-aminoclonazolam metabolite detected; cause of death: cerebral and respiratory depression. paf.0000000000000803
Death was attributed to combined CNS and respiratory depression.supported
Combined CNS depression attributed as cause of death. bkac098
Population-level data from Victoria, Australia demonstrate increasing novel benzodiazepine involvement in fatal overdoses over recent years.supported
Increasing NPS benzodiazepine-related fatalities in Victoria, Australia; temporal trend analysis. dar.14054
Amnesia occurs at sub-sedating doses, creating periods of anterograde memory loss during which the individual remains ambulatory and superficially functional — a state conducive to dangerous behavior, accidental injury, and unknowing redosing. Delusions of sobriety — the subjective experience of being less impaired than objective measures indicate — compound this risk by suppressing the self-monitoring that would otherwise prevent further dose escalation.partially supported
notes clonazolam can cause strong sedation and amnesia at doses as low as 0.5 mg wps.20236
Pérez Orts et al. identified the compound as a DFSA-relevant substance due to its combination of rapid onset, high potency at low doses, profound amnesia at sub-sedating concentrations, and limited detectability in standard immunoassays.supported
DBZDs active at low doses, fast onset, ideal for DFSA; reviews ADME properties and detection in biological matrices. bkac017
Papsun et al. detected clonazolam and 8-aminoclonazolam in impaired-driving blood samples over a 5-year surveillance period (2017–2021); observed driving behavior was consistent with CNS depressant effects including lane deviation, slowed reaction time, and impaired coordination.supported
1,145 DBZDs in 805 DUID blood samples 2017-2021; clonazolam/8-aminoclonazolam detected; driving consistent with CNS depressant impairment. bkad036
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Claim in safety — inconclusiveinconclusiveworking →
Reeves et al. documented difficulties in outpatient management, Peng et al. described diagnostic challenges in identifying the specific agent in designer benzodiazepine dependence, and Frost et al. reported on detoxification of NPS-dependent patients in Norwegian clinical settings.supported
Case report on designer benzodiazepine dependence management; discusses challenges of outpatient treatment. 10550887.2022.2117510
Reeves et al. documented difficulties in outpatient management, Peng et al. described diagnostic challenges in identifying the specific agent in designer benzodiazepine dependence, and Frost et al. reported on detoxification of NPS-dependent patients in Norwegian clinical settings.supported
Case report illustrating difficulties of diagnosing and managing DBZD sedative-hypnotic use disorder. adm.0000000000000869
Reeves et al. documented difficulties in outpatient management, Peng et al. described diagnostic challenges in identifying the specific agent in designer benzodiazepine dependence, and Frost et al. reported on detoxification of NPS-dependent patients in Norwegian clinical settings.supported
Norwegian case series of NPS detoxification including designer BZDs. tidsskr.23.0668
Management is extrapolated from general benzodiazepine withdrawal literature: substitution with a long-acting benzodiazepine (typically diazepam) followed by gradual dose reduction over weeks to months, with the taper rate adjusted according to clinical responsesupported
Management of benzodiazepine dependence: gradual withdrawal, switch to long-acting BZD. austprescr.2015.078
The fatal polysubstance case documented by Theofel et al. exemplifies this risk: clonazolam and flualprazolam combined with opioid alkaloids (thebaine, codeine, morphine) and a synthetic cannabinoid to produce lethal respiratory failure.partially supported
Fatal polysubstance case; clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L; opiates also detected. Combined CNS depression attributed as cause of death. bkac098
Su et al. quantified the mortality risk of concurrent opioid-benzodiazepine use, reporting a hazard ratio of 1.78 for mortality compared to opioids alonesupported
concurrent opioid-BZD use significantly increases 1-year all-cause mortality: continuous BZD use aHR 1.78 prp2.70215
Claim in safety — inconclusiveinconclusiveworking →
Concurrent opioid use: The additive respiratory depression mechanism is the best-documented lethal interaction for clonazolam.supported
Fatal polysubstance case; clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L; opiates also detected. Combined CNS depression attributed as cause of death. bkac098
Concurrent opioid use: The additive respiratory depression mechanism is the best-documented lethal interaction for clonazolam.supported
Concurrent opioid-BZD use significantly increases 1-year all-cause mortality: continuous BZD use aHR 1.78 prp2.70215
Pediatric populations: The Moore et al. fatality involved a 14-year-old, demonstrating extreme vulnerability in adolescent populations.supported
14-year-old male found unresponsive after ingesting tablets thought to be Xanax paf.0000000000000803
Standard benzodiazepine urine immunoassays show variable but generally high cross-reactivity with clonazolam in KIMS II, CEDIA, and EMIT II Plus platformssupported
Cross-reactivity of 13 designer benzodiazepines including clonazolam in four immunoassays; generally high cross-reactivity detected. dta.2003
history9 · 6 ok
A critical public health concern is its incorporation into counterfeit pharmaceutical tablets — particularly fake alprazolam (Xanax) tablets — a phenomenon confirmed by wastewater epidemiology and by the Moore et al. fatality case, in which a 14-year-old victim believed he was consuming pharmaceutical alprazolamsupported
Detection of illicit BZDs including clonazolam, flubromazolam in wastewater; sold as counterfeit Xanax. j.scitotenv.2022.158061
A critical public health concern is its incorporation into counterfeit pharmaceutical tablets — particularly fake alprazolam (Xanax) tablets — a phenomenon confirmed by wastewater epidemiology and by the Moore et al. fatality case, in which a 14-year-old victim believed he was consuming pharmaceutical alprazolamsupported
14-year-old male found unresponsive after ingesting tablets thought to be Xanax paf.0000000000000803
Claim in history — inconclusiveinconclusiveworking →
Clonazolam began appearing on illicit online drug markets in approximately 2014supported
Clonazolam first emerged in global illicit drug markets in 2014. 15563650.2023.2183105
Claim in history — inconclusiveinconclusiveworking →
The broader designer benzodiazepine phenomenon had begun around 2007 with substances such as phenazepam, but the clonazolam-era triazolobenzodiazepines represented a significant potency escalation within the NPS benzodiazepine market.supported
first DBZDs appeared as NPS around 2007; 29 DBZDs notified to EMCDDA. 1570159x18666200110121333
Australian wastewater monitoring has independently confirmed community-level clonazolam use.supported
Clonazolam detected in NSW and Queensland wastewater during New Year 2021-22. j.talanta.2022.123767
Claim in history — inconclusiveinconclusiveworking →
Moosmann et al. noted that it was unclear whether designer benzodiazepines were covered by the Controlled Substances Analogue Enforcement Act of 1986.supported
discusses legal challenges and public health risks. wps.20236
pharmacology9 · 8 ok
Claim in pharmacology — inconclusiveinconclusiveworking →
Computational QSAR modeling and molecular docking studies conducted against crystallized GABA-A receptor structures (PDB: 6HUO, 6HUP) have predicted high biological activity for clonazolam, consistent with optimal placement of hydrophobic and polar functional groups within the benzodiazepine binding pocket.supported
QSAR and docking analysis of 101 designer BZDs for GABA-A receptor binding; 41% predicted high biological activity; docking on crystallised GABA-A receptors. ph14080720
Relative potency data, derived from review literature and user reports rather than controlled pharmacological studies, indicate that clonazolam is more than twice as potent as alprazolam in terms of effective dosesupported
reported to be over twice as potent as alprazolam neurolint14030053
Relative potency data, derived from review literature and user reports rather than controlled pharmacological studies, indicate that clonazolam is more than twice as potent as alprazolam in terms of effective dosesupported
Analysis of user trip reports for designer benzodiazepines; discusses pharmacological effects and potencies including structure-activity relationships. 0269881119901096
Strong sedation and amnesia occur at oral doses as low as 0.5 mg (500 µg).supported
notes clonazolam can cause strong sedation and amnesia at doses as low as 0.5 mg wps.20236
The most comprehensive metabolism study was conducted by Kong et al. using human liver microsomes (HLM) and zebrafish in vivo models with liquid chromatography–quadrupole Orbitrap mass spectrometrysupported
Comprehensive metabolic profiling of clonazolam in HLMs and zebrafish... liquid chromatography quadrupole Orbitrap mass spectrometry j.jchromb.2022.123583
The predominance of the amino metabolite over the parent compound in biological specimens was confirmed in the Moore et al. fatality case, where 8-aminoclonazolam was detected at 140 ng/mL in postmortem blood while the parent compound was not separately reported.supported
140 ng/mL 8-aminoclonazolam metabolite detected; cause of death: cerebral and respiratory depression paf.0000000000000803
Earlier in vitro work by El Balkhi et al. using HLM incubation with triple quadrupole mass spectrometry identified denitro-, mono- and di-hydroxylated, and desmethyl metabolites of clonazolam, consistent with the Kong et al. findings.supported
In vitro metabolite profiling of 8 DBZDs including clonazolam using HLMs; identified denitro-, mono- or di-hydroxylated and desmethyl metabolites. s00414-017-1541-6
Phase I and II metabolism follows pathways similar to classical benzodiazepines, and by structural analogy with alprazolam and clonazepam, CYP3A4 is the most likely primary metabolizing enzymesupported
notes phase I and II metabolism similar to traditional BZDs; CYP polymorphisms not yet clarified. aiht-2023-74-3771
pharmacokinetic-detail5 · 5 ok
Fatal mono-intoxication: 8-aminoclonazolam at 140 ng/mL in postmortem blood; parent compound not separately quantifiedsupported
First reported death from clonazolam alone; 140 ng/mL 8-aminoclonazolam metabolite detected paf.0000000000000803
Fatal polysubstance case: Clonazolam at 2.08 mg/L (2,080 ng/mL) in postmortem blood, alongside flualprazolam and opioidssupported
Fatal polysubstance case; clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L; opiates also detected. bkac098
The Kong et al. metabolism study identified seven Phase I metabolites and two Phase II conjugates in the zebrafish modelpartially supported
Identified 7 Phase I and 1 Phase II metabolites. j.jchromb.2022.123583
The relative contribution of each pathway in humans is not fully established, though the El Balkhi et al. HLM study confirmed that denitro, hydroxylated, and desmethyl metabolites are formed under human hepatic conditions.supported
In vitro metabolite profiling of 8 DBZDs including clonazolam using HLMs; identified denitro-, mono- or di-hydroxylated and desmethyl metabolites. s00414-017-1541-6
DUID samples: Clonazolam and 8-aminoclonazolam detected in impaired-driving blood specimens over a 5-year surveillance period (2017–2021)supported
1,145 DBZDs in 805 DUID blood samples 2017-2021; clonazolam/8-aminoclonazolam detected bkad036
summary5 · 3 ok
It appeared on illicit online drug markets in approximately 2014 and has since been the subject of WHO critical review, multiple fatality investigations, and regulatory scheduling actions in the United States, United Kingdom, and Australiapartially supported
Clonazolam first emerged in global illicit drug markets in 2014. 15563650.2023.2183105
Claim in summary — inconclusiveinconclusiveworking →
The subjective effect profile — dominated by sedation, amnesia, muscle relaxation, anxiolysis, and disinhibition — is consistent with non-selective GABA-A positive allosteric modulation. Delusions of sobriety and compulsive redosing are commonly reported and constitute a distinctive risk signature.partially supported
effects include heavy hypnosis, sedation, amnesia, anxiolysis, muscle relaxation, euphoria neurolint14030053
The first confirmed single-substance fatality involved a 14-year-old who ingested counterfeit alprazolam tablets containing clonazolamsupported
First reported death from clonazolam alone; 14-year-old male found unresponsive after ingesting tablets thought to be Xanax paf.0000000000000803
Claim in summary — inconclusiveinconclusiveworking →
clinical-evidence4 · 2 ok
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Claim in clinical-evidence — inconclusiveinconclusiveworking →
Carpenter et al. (2019): Population-level exposure data from the US National Poison Data System (2014–2017), documenting designer benzodiazepine exposures including clonazolam.supported
Analysis of designer benzodiazepine exposures in NPDS 2014-2017. 15563650.2018.1510502
Bäckberg et al. (2019): Swedish STRIDA project surveillance data on NPS benzodiazepine intoxications including clonazolam.supported
Bioanalytical and clinical data from NPS BZD intoxications in the Swedish STRIDA project. 15563650.2018.1506130
comparative-pharmacology3 · 2 ok
Clonazolam is estimated to be more than twice as potent as alprazolam by effective dose, based on typical recreational doses of 200–400 µg versus alprazolam's 500–2,000 µg range.partially supported
reported to be over twice as potent as alprazolam neurolint14030053
Claim in comparative-pharmacology — inconclusiveinconclusiveworking →
Flualprazolam: Co-detected with clonazolam in the Theofel et al. fatal polysubstance case (clonazolam 2.08 mg/L, flualprazolam 0.74 mg/L).supported
clonazolam blood concentration 2.08 mg/L; flualprazolam 0.74 mg/L bkac098
legal-status2 · 1 ok
Prior to specific scheduling, its legal status was uncertain in many countries — Moosmann et al. noted in 2015 that it was unclear whether designer benzodiazepines were covered by existing analogue legislation.supported
discusses legal challenges and public health risks. wps.20236
Claim in legal-status — inconclusiveinconclusiveworking →
chemistry1 · 0 ok
Claim in chemistry — inconclusiveinconclusiveworking →
neuroscience1 · 0 ok
Claim in neuroscience — inconclusiveinconclusiveworking →
receptor-pharmacology1 · 1 ok
Catalani et al. conducted QSAR modeling and molecular docking against crystallized GABA-A receptor structures (PDB accession codes 6HUO and 6HUP), predicting high biological activity for clonazolamsupported
QSAR and docking analysis of 101 designer BZDs for GABA-A receptor binding; 41% predicted high biological activity; docking on crystallised GABA-A receptors. ph14080720